|
|
||||||||
From INSERM U679 (former U289), Federative Institute for Neuroscience Research (IFR70), Salpêtrière Hospital, Paris, France (M.N., P.R., I.N., S.F., C.D., G.S., M.R., A.D., A.B.); Department of Genetics Cytogenetics and Embryology (P.R., G.S., A.D., A.B.) and Federation of Neurology (A.B.), AP-HP, Salpêtrière Hospital, Paris, France; Salpêtrière Medical School, Pierre and Marie Curie University, Paris, France (A.B.); Centre Hospitalier Universitaire de Besançon, Besançon, France (F.F.); and Department of Neurogenetics, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France (C.G.).
Address correspondence and reprint requests to Dr. Alexandra Dürr, INSERM U679 (former 289), Hôpital de la Salpêtrière, 47, Boulevard de lHôpital, 75651, Paris Cedex 13, France; e-mail: durr{at}ccr.jussieu.fr
Seven families with six different SPG3A mutations were identified among 106 with autosomal dominant hereditary spastic paraplegia (HSP). Two mutations were novel (T162P, C375R). SPG3A was twice as frequent as SPG4 in patients with onset before age 10 years (31.8%). Later onset was not observed. The phenotype was pure HSP, but disease duration was longer than in non-SPG3A/SPG4 patients, leading ultimately to greater handicap.
Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the January 10 issue to find the title link for this article.
Supported by grants from the French National Institute for Health and Medical Research, the VERUM foundation (A.B.), the GIS/Rare Diseases Institute (A02191DS-SPATAX; A.D.), Lilly (Japan; M.N.), the French Foreign Ministry (M.N.), la Fondation Recherche Médicale (M.N.), Collège de Médecine des Hôpitaux de Paris (P.R.), and European Neurological Society (P.R.).
Disclosure: The authors report no conflicts of interest.
Received July 7, 2005. Accepted in final form September 28, 2005.
This article has been cited by other articles:
![]() |
N. Rismanchi, C. Soderblom, J. Stadler, P.-P. Zhu, and C. Blackstone Atlastin GTPases are required for Golgi apparatus and ER morphogenesis Hum. Mol. Genet., June 1, 2008; 17(11): 1591 - 1604. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Beetz, R. Schule, T. Deconinck, K.-N. Tran-Viet, H. Zhu, B. P.H. Kremer, S. G.M. Frints, W. A.G. van Zelst-Stams, P. Byrne, S. Otto, et al. REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31 Brain, April 1, 2008; 131(4): 1078 - 1086. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ivanova, K. G. Claeys, T. Deconinck, I. Litvinenko, A. Jordanova, M. Auer-Grumbach, J. Haberlova, A. Lofgren, G. Smeyers, E. Nelis, et al. Hereditary Spastic Paraplegia 3A Associated With Axonal Neuropathy Arch Neurol, May 1, 2007; 64(5): 706 - 713. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Beetz, A.O.H. Nygren, J. Schickel, M. Auer-Grumbach, K. Burk, G. Heide, J. Kassubek, S. Klimpe, T. Klopstock, F. Kreuz, et al. High frequency of partial SPAST deletions in autosomal dominant hereditary spastic paraplegia Neurology, December 12, 2006; 67(11): 1926 - 1930. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Wood, J. A. Landers, M. Bingley, C. J. McDermott, V. Thomas-McArthur, L. J. Gleadall, P. J. Shaw, and V. T. Cunliffe The microtubule-severing protein Spastin is essential for axon outgrowth in the zebrafish embryo Hum. Mol. Genet., September 15, 2006; 15(18): 2763 - 2771. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-P. Zhu, C. Soderblom, J.-H. Tao-Cheng, J. Stadler, and C. Blackstone SPG3A protein atlastin-1 is enriched in growth cones and promotes axon elongation during neuronal development Hum. Mol. Genet., April 15, 2006; 15(8): 1343 - 1353. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |